Study of ERAS-801 for recurrent or newly diagnosed glioblastoma with EGFR changes
Part of Cancer clinical trials.
This trial tests an experimental drug called ERAS-801 for people with a type of brain cancer called glioblastoma or gliosarcoma that has a specific genetic change (EGFR amplification or mutation). The study has two groups: one for people whose tumor has come back after treatment, and another for older adults (70+) who are newly diagnosed. The drug targets the EGFR pathway, which may help slow tumor growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older (for the recurrent group) or 70 years or older (for the newly diagnosed group).
- You must have a diagnosis of glioblastoma or gliosarcoma that is either recurrent after prior treatment or newly diagnosed (for older adults).
- Your tumor must have a particular genetic change in the EGFR gene (amplification or mutation) as determined by a lab test, but not specific EGFR mutations like T790M or exon 20.
- You must be able to undergo MRI scans and have tumor tissue available from a previous surgery.
- You must have adequate kidney, liver, and blood function, and be able to take oral medication.
- You must not have taken certain EGFR inhibitors before, and you must not be on enzyme-inducing anti-seizure medications.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two new investigational drugs (ABBV-637, ABBV-155) combined with another drug (ERAS-801) for people with glioblastoma. The goal is to see if this combination can shrink the tumor or slow its growth. You need to have a specific genetic marker (EGFR amplification) in your tumor to be eligible.
This trial tests a new drug called CM93 that targets a specific change (EGFR) in recurrent glioblastoma, a type of brain cancer. The goal is to see if it can slow or stop tumor growth and to find the best dose.
This trial tests a personalized immune cell treatment for a glioblastoma brain tumor that has a specific marker called EGFRvIII. The cells are made in a lab and given by infusion, and the study aims to see if they can safely target and attack the tumor.
This early study looks at a treatment plan (including resection/surgery and an added medicine) for glioblastoma that has come back after standard therapy. The goal is to see how well it controls tumor growth and whether it is tolerable.
This trial tests a combination of two experimental drugs, CTX-009 and CTX-471, for people whose glioblastoma has returned. The goal is to see if these drugs can help control the tumor.
This trial tests a radioactive drug that targets a protein on tumor blood vessels to treat glioblastoma that has come back after standard treatment. It may help shrink tumors or slow their growth.
Hear when a new Glioblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.